Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers

MolDX covers MRD testing for specified hematologic cancers (ClonoSeq covered for ALL, MM, CLL, DLBCL, and mantle cell lymphoma) and covers established single-gene PCR MRD tests (e.g., BCR-ABL1) per guidelines. Billing requires registration with the DEX Diagnostic Exchange and submission of the assigned DEX Z-Code with claims (1 UOS); NGS multi-analyte panels use CPT 81479 with DEX Z-Code. Testing is limited to ≤1 test per 30 days and NGS-based MRD is generally limited to one episode per patient per cancer diagnosis unless there is clinical evidence of genetic change.

"ClonoSeq (Adaptive Biotechnologies) MRD testing is covered for patients with acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymp..."

Sign up to see full coverage criteria, indications, and limitations.